Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, ...

Holiday weight gain hits home for many come January. These days, folks making resolutions to slim down and get fit have an ...

Ozempic, Wegovy and Mounjaro, all GLP-1 anti-obesity medications, may offer health benefits beyond weight loss. Studies show ...

Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to ...

Although bipartisan legislation to provide Medicare coverage for obesity treatments has circulated in Congress for more than ...

Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things to look for include more widespread adoption of artificial intelligence ...

A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on ...

Dr. Mehmet Furkan Burak said people who have lost weight and then gained it again can feel guilt or shame and blame ...

For Floridians, 2024 was a year of weight loss and emerging revelations about anti-obesity medications. More than an ...

Overall, average healthcare costs increased 46% over two years for patients trying GLP-1 drugs for obesity, from $12,695 to $18,507. The Congressional Budget Office states that there does not ...

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...